Ibrahim Alaa M, Said Mahmoud M, Hilal Amany M, Medhat Amina M, Abd Elsalam Ibrahim M
Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.
Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Tumour Biol. 2020 Oct;42(10):1010428320963811. doi: 10.1177/1010428320963811.
This study aimed at investigating the expression of candidate microRNAs (miRs), at initial diagnosis, during neoadjuvant chemotherapy, and after the tumor resection in locally advanced breast cancer patients. Plasma samples were collected from locally advanced breast cancer patients (n = 30) and healthy subjects (n = 20) for the detection of candidate miRs' expression using the real-time quantitative polymerase chain reaction. At initial locally advanced breast cancer diagnosis, the expression of miR-21, miR-181a, and miR-10b was significantly increased, whereas that of miR-145 and let-7a was significantly decreased, compared to the healthy individuals. The diagnostic accuracy of miR-21 was superior to both carcinoembryonic antigen and carcinoma antigen 15-3 as diagnostic biomarkers for locally advanced breast cancer. By the end of the treatment, the expression of altered miRs rebound to control values. The expression levels of candidate plasma miRs are useful diagnostic biomarkers, as well as monitoring a proper response for locally advanced breast cancer patients to the treatment. Furthermore, miR-10b and miR-21 can be considered as predictive biomarkers for progression-free survival.
本研究旨在调查局部晚期乳腺癌患者在初诊时、新辅助化疗期间以及肿瘤切除后的候选微小RNA(miR)表达情况。采集局部晚期乳腺癌患者(n = 30)和健康受试者(n = 20)的血浆样本,采用实时定量聚合酶链反应检测候选miR的表达。在局部晚期乳腺癌初诊时,与健康个体相比,miR-21、miR-181a和miR-10b的表达显著增加,而miR-145和let-7a的表达显著降低。作为局部晚期乳腺癌的诊断生物标志物,miR-21的诊断准确性优于癌胚抗原和癌抗原15-3。治疗结束时,miR表达的改变恢复至对照值。候选血浆miR的表达水平是有用的诊断生物标志物,也是监测局部晚期乳腺癌患者对治疗的适当反应的指标。此外,miR-10b和miR-21可被视为无进展生存期的预测生物标志物。